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OBJECTIVES: Racial disparities in diabetics exist in diabetes
control, as well as complications associated with diabetes. Such
disparities could lead to difference in likelihood of hospitaliza-
tion among different races. This study examined the association
between patients’ race and hospitalization in type 2 diabetes
patients newly starting oral antidiabetic therapy. METHODS:
This was a retrospective cohort study of Medicaid insured
patients with type-2 diabetes newly starting oral antidiabetic
medication (metformin, sulfonylureas, thiazolidinediones). A
cohort of type 2 diabetes patients was identiﬁed using ICD-9
code (250.xx) and 1 National Drug Code for antidiabetic med-
ication. Information for demographic factors (race, age of
patient, gender of the patient), clinical factors (severity of dia-
betes, number of comorbidities), medication related factors
(number of medications consumed), and access to care (number
of diabetes related physician visits) was extracted from the data-
base. Patients’ race was categorized as African Americans,
Whites and Others. Hospitalization was measured as a categor-
ical dichotomous variable. Patients were followed up for one
year after the index date of new medication. Multiple logistic
regression for three cohorts was performed to assess the associ-
ation patients’ race and likelihood of hospitalization adjusting
for above mentioned factors. RESULTS: Among metformin users
(n = 215), there was no difference in the likelihood of hospital-
ization between races. Among sulfonylureas users (n = 1171),
there was no difference in the likelihood of hospitalization
between races. Among thiazolidinedione users (n = 1751),
African Americans were associated with 39% increased likeli-
hood of hospitalization as compared to whites (OR: 1.39, 95%
CI: 1.07–1.81). Number of medications and comorbidities were
found to be signiﬁcant predictors in each of the analyses. CON-
CLUSION: Racial differences in hospitalizations among thiazo-
lidinediones users should be investigated to understand other
factors that contribute to hospitalization in this group. Avoiding
hospitalization among these patients would generate consider-
able cost savings.
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OBJECTIVES: To determine: 1) the utilization and expenditures
of pioglitazone after the decision of drug reimbursement, and 2)
the addition (adding of pioglitazone to the treatment) or substi-
tution (switching from other anti-diabetic agents to pioglitazone)
effect of pioglitazone introduction. METHODS: Retrospective
database analysis was carried out from the payer’s (BNHI) per-
spective. Overall treatment resource from 5-year BNHI claimed-
database of diabetic patients (ICD-9-CM: 250.XX), including
OPD and hospitalized data from January 2000 to December
2004, were extracted. However, only pharmaceutical expendi-
tures of anti-diabetic agents were analyzed. Drug prices were
BNHI reimbursed prices, and discount rate was not considered.
RESULTS: Five-year database contains population of 0.92, 0.98,
1.02, 1.05 and 1.14 million people from 2000 to 2004 respec-
tively in Taiwan with diabetes (including type 1 and type 2 DM).
In 2002, the expenditure of pioglitazone reimbursed by BNHI
was NT$ 37.2 million (1.02% of total anti-diabetic agents), and
it increased signiﬁcantly in 2003 (NT$ 231.2 million) and 2004
(NT$ 359.4 million) but approached saturation at last few
months of 2004. It was assumed that if the anti-diabetic agents
were not substituted by pioglitazone, patients would still be
using them for one year. The effect of drug substitution in 2002,
2003 and 2004 were NT$ 14.4 million, 61.4 million and 41.4
million, respectively. The order of substitution by expenditure of
pioglitazone was rosiglitazone, acarbose and metformin. Sub-
tracting the substituted expenditure, the reimbursement of
pioglitazone only burdened insurer NT$ 22.8 million, NT$
169.7 million and NT$ 318.0 million in 2002, 2003 and 2004,
respectively. The cost effect of adverse drug reactions is difﬁcult
to evaluate in the retrospective data analysis. CONCLUSION:
The ﬁnancial burden of introducing the new drug to a health
insurance program should not consider only the expenditure of
the new drug itself. The substitution effect should be deducted
in the budget impact analysis.
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OBJECTIVES: To conduct a cost-beneﬁt analysis (CBA) for
inhaled drug delivery system for insulin (INI). METHODS: Pre-
viously, we reported the average monthly willingness-to-pay
(WTP) for INI from diabetic patient (Cdn$153.70 ± $99.90) 
and general population (Cdn$68.59 ± $44.65) perspective in
Canada. This study estimates the net beneﬁt and cost-beneﬁt
ratio for INH from both patient and general population per-
spective. The average cost of insulin therapy using subcutaneous
insulin injection (SCI) was calculated equal to Cdn$32.40 per
month based on average 40 units daily usage of rapid acting
insulin for bolus insulin supplement. The cost of self-injection
was approximately Cdn$8.40. One form of INI is available using
powder form of insulin and a liquid inhaler is under develop-
ment. The average daily cost of inhaled delivery system for
insulin is approximately 40% higher than SCI. Using the same
price premium ratio we estimated the average monthly cost of
INI in Canada equal to Cdn$45.36 (when being available). The
cost of basal insulin and self blood-glucose monitoring was con-
sidered equal. RESULTS: In the base-case scenario, the net
beneﬁt of INI when compared to SCI was Cdn$90.74 per month
from the diabetic patient perspective and Cdn$5.63 from the
general population perspective. The cost-beneﬁt ratio (CBR—
calculated as ÄCost/ÄWTP) from the patient (0.12) and the
general population (0.69) perspective were <1, suggestive of a
positive CBR for INI. Extensive sensitivity analysis was per-
formed by changing variables (set apriori) including INI price
(+10%, 20%) and daily usage of insulin units (±10%, 20%).
Results of the analysis were robust to the changes in variables.
CONCLUSION: This analysis demonstrated that the beneﬁts of
inhaled delivery system for insulin for control of blood glucose
levels in diabetic patients are greater than the costs, therefore
The rapy provide a positive net beneﬁt from both patient and
general population perspective and is a good investment for
money.
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